Some people may remain ill after COVID infection because the virus still lurks in their bodies. The looming question now is: ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Samuel Salvaggio Senior Trial Design Lead, One2Treat ...

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with ...

Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...

Supernus Pharmaceuticals said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its shares down 22% aftermarket.

Clinical trial complexity has significantly increased in the past decade. How can the industry adapt and innovate to remain ...

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), a ...

A new study will investigate whether prenatal antibiotic use impairs breast milk immune function and disrupts neonatal gut ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

The HALO™ Clarity is powered by Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS) technology, delivering non-invasive, deep-brain stimulation without the use of drugs or invasive ...

AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing a first-in-class therapeutic for peripheral ...